��������

Harm Hermsen has over two decades of work experience in the field of regulatory affairs and biotech. Harm is currently the Vice President of Global Regulatory Affairs at uniQure, where they have been since 2020. Prior to that, Hermsen worked as a Senior Director of Regulatory Affairs at uniQure from 2020 to 2021. Harm also has experience as a Principal Consultant at ProPharma Group, specializing in biotech, cell, and gene therapy from 2019 to 2020. Hermsen served as a member of the Gene Therapy Working Party at the European Directorate for the Quality of Medicines and Healthcare from 2007 to 2020. Harm was also the Chief Regulatory and Quality Officer at Glycostem Therapeutics in 2019. Before that, they held positions at Xendo as a Principal Consultant and Managing Consultant in Regulatory Affairs from 2012 to 2019. Hermsen's earlier experience includes roles as a senior pharmaceutical scientist and senior assessor of biological medicines at the College ter Beoordeling van Geneesmiddelen from 2007 to 2011, a member of the Gene Therapy Working Party at the European Medicines Agency from 2008 to 2011, and an expert in Gene Therapy at the ICH gene therapy discussion group from 2007 to 2011. Harm began their career as a Project Leader and Assessor at the GMO office of RIVM from 2002 to 2006, and as the Secretary of the Advisory Commission on Genetic Modification at COGEM from 2000 to 2002. Hermsen has a wealth of experience and expertise in the regulatory and biotech industries.

Harm Hermsen attended the Hogeschool van Arnhem en Nijmegen from 1989 to 1993 where they received a Bachelor of Science (B.Sc.) degree in Biotechnology. Harm then pursued a Master of Science (M.Sc.) degree in Biochemistry, Molecular Biology, and Cell Biology from the University of Nijmegen from 1992 to 1996. Following that, they completed their education at the University of Nijmegen with a Doctorate (Dr.) degree in Biochemistry, Molecular Biology, and Cell Biology from 1996 to 2000.